Epiphen

Quick links to important sections

Epiphen

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epiphen

Property Description
Active ingredient Phenobarbital
Form Tablet, Oral Solution, Injectable Solution
Pharmacological class Anticonvulsant (Antiepileptic Drug), Barbiturate
General use Promoting neurological stability and seizure control
Origin Synthetic compound

What Type of Medicine is Epiphen?

Epiphen is a prescription-only medicine that is chemically categorized as a synthetic anticonvulsant drug containing the active ingredient Phenobarbital. This medicine is firmly classified within the barbiturate pharmacological class, distinguishing it as one of the long-acting derivatives of barbituric acid. Its primary identity is that of an antiepileptic drug (AED), intended for the long-term modulation of electrical activity in the brain. Phenobarbital is recognized as an essential medicine due to its established profile in treating seizure disorders across various healthcare systems. This status is supported by clinical observations confirming its utility as a foundational AED. Unlike treatments derived from natural sources, the active compound Phenobarbital is manufactured as a precise synthetic compound, which ensures consistency and specific pharmacological properties suitable for managing chronic neurological conditions.


Composition, Forms, and General Purpose

Epiphen is a single-ingredient product, with its therapeutic action provided exclusively by Phenobarbital. The medicine is supplied in multiple preparations to suit different patient needs, including solid tablets for routine oral administration, and a liquid oral solution or an injectable solution for situations requiring alternative routes of administration. This availability ensures clinical flexibility for diverse patient populations, such as those with difficulty swallowing.

This drug's general purpose is to promote neurological stability by controlling and reducing the frequency of abnormal and excessive electrical discharges in the brain. This stabilizing effect is achieved by enhancing the brain's natural inhibitory systems, thereby reducing the overall excitability of nerve cells. The mechanism of action involves decreasing how quickly the brain and nervous system send messages, which helps prevent uncontrolled electrical bursts and is utilized for maintaining steady-state treatment. A typical scenario for its use involves long-term management to prevent recurrent, spontaneous seizures.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH MedlinePlus

What side effects are possible with Epiphen?

Possible side effects and safety information

The safety profile of Epiphen, which contains the active ingredient Phenobarbital, is defined by regulatory documents based on classified adverse reactions and specific safety constraints. The most frequently documented effects are related to Central Nervous System (CNS) depression.

Officially Documented Adverse Reactions

The most common adverse reactions include drowsiness, sedation, lethargy, ataxia, and cognitive impairment. These are often observed at the beginning of treatment.

Less frequently, the official labels document serious systemic and psychiatric concerns. These include the rare but potentially fatal Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which carry the highest risk during the initial weeks of therapy. Furthermore, the risk of suicidal ideation and behavior is documented for antiepileptic drugs, including Phenobarbital.

System-Organ Class Common Adverse Reaction Entities
Nervous System Disorders Ataxia, Nystagmus, Sedation
Psychiatric Disorders Dependence, Paradoxical excitement, Confusion
Skin Disorders Rash, Urticaria (SJS/TEN listed as Rare)

Regulatory Safety Patterns and Constraints

Specific safety considerations are noted for certain populations. Older adults may be more susceptible to CNS effects like confusion. Children may experience paradoxical reactions, such as hyperactivity or aggression, rather than sedation. Phenobarbital is explicitly restricted in patients with severe hepatic or renal impairment, and is absolutely contraindicated in patients with acute intermittent porphyria.

Long-term exposure is associated with risks of drug dependence and decreased bone mineral density. The official label strictly prohibits the abrupt cessation of the medicine due to the documented risk of precipitating a severe, potentially life-threatening withdrawal syndrome.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Epiphen (Phenobarbital) overdose is strictly defined by its effects as a powerful Central Nervous System (CNS) depressant. Documented presentations can range from moderate intoxication—which is officially described as resembling alcoholic inebriation and involving slurred speech and incoordination—to severe intoxication resulting in profound CNS depression and coma.

Overdose constitutes a serious, life-threatening risk primarily due to the potential for respiratory depression and apnea (cessation of breathing). Cardiovascular instability, manifesting as severe hypotension (low blood pressure) and the risk of circulatory collapse, is also a critical outcome documented in regulatory labeling.

Immediate emergency medical attention must be sought if an individual collapses, experiences a seizure, has trouble breathing, or cannot be awakened. This is a regulator-mandated action when severe manifestations occur. There is no specific antidote for Phenobarbital listed in regulatory documents. Therefore, official management relies entirely on symptomatic and supportive therapy, including procedures such as meticulous monitoring of vital signs, gastric lavage, and the maintenance of adequate respiratory and hemodynamic exchange.

Therapeutic Uses of Epiphen

What Epiphen Treats: Main Uses and Benefits

Epiphen (Phenobarbital) is a commonly used anti-seizure medication applied in clinical settings that involve acute or unstable symptom patterns, providing supportive symptomatic relief and management. Clinical applications include the control of seizures, the relief of anxiety, and the prevention of withdrawal symptoms associated with dependence on other barbiturate medications.

Controlling Chronic Seizure Disorders

This medication is generally used for the long-term management of epilepsy, particularly generalized and partial seizure types. The medication helps reduce the frequency and intensity of recurrent seizure episodes, which assists with maintaining functional stability. It is applied across conditions characterized by episodic or fluctuating manifestations that interfere with daily functioning. The relevant therapeutic areas include supporting the management of long-term seizure disorders, acute episodes of hyperexcitability, severe substance withdrawal, and specific seizure presentations in children.


Stabilizing Acute Neurological Crises and Specialized Uses

Epiphen is also relevant in managing acute symptomatic episodes marked by heightened patient distress. This includes its use in rapidly managing prolonged seizure episodes and providing a calming effect during severe substance withdrawal. The medication is commonly used in specific patient groups, such as treating seizures in newborns (neonatal seizures) and may be part of symptomatic management against recurrent febrile seizures in children.


Quick Fact: Relief for Heightened Symptom Activity
This medication provides supportive relief when symptoms that create noticeable physiological strain interfere with routine activities, contributing to improved comfort and helping to maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Epiphen, a veterinary medicine containing phenobarbital for the control of epilepsy in dogs, has strict regulatory guidelines defining appropriate use.

Contraindications (Must Not Use)

Epiphen must not be administered to animals with impaired hepatic function (liver disease) or those with a known hypersensitivity to phenobarbital or other barbiturates. It is also contraindicated for use in pregnant animals and is generally not recommended in animals with serious renal or cardiovascular/respiratory disorders.


Restricted or Cautionary Use

Use requires special consideration and a careful benefit-risk assessment by a licensed veterinarian in animals with:

  • Impaired renal function (kidney issues).
  • Hypovolemia (low blood volume) or anemia.
  • Cardiac or respiratory dysfunction.
  • Lactation (nursing): Use should be limited, and the puppies must be monitored for adverse sedative effects.
  • Age: Safety has not been established in animals under six months of age or in breeding dogs.

This medication is restricted by law to use by or on the order of a licensed veterinarian, who must closely monitor the patient’s clinical status and blood levels throughout therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Epiphen (Phenobarbital) is documented by regulatory authorities to engage in significant drug interactions, primarily through hepatic enzyme induction, a pharmacokinetic mechanism that accelerates the metabolism of many co-administered substances. This induction generally causes a reduction in the plasma concentration and therapeutic effect of the interacting drug.

Key Documented Interaction Patterns

Interaction Type Examples of Interacting Substances Official Outcome
Hepatic Enzyme Induction Oral Contraceptives, Oral Anticoagulants (Warfarin), Corticosteroids Decreased efficacy and plasma levels of the co-administered drug.
Additive CNS Depression Alcohol, Opioid Analgesics, Other Sedatives Increased risk of profound sedation and respiratory depression.
Variable Exposure Sodium Valproate, Phenytoin Valproate increases Phenobarbital levels; Phenytoin's effect is variable and unpredictable.

Formal Restrictions and Contraindications

Epiphen is formally contraindicated in patients with a history of acute intermittent porphyria due to the risk of precipitating a life-threatening attack. The official label also prohibits co-administration with strong CYP3A4-metabolized antivirals (e.g., atazanavir, darunavir) and Sodium Oxybate due to documented loss of therapeutic effect or severe pharmacodynamic synergism. Long-term use is associated with risks of folate and vitamin D deficiency.

Mechanism of Action

Epiphen is a formulation of phenobarbital, a barbiturate derivative. Its primary mechanism of action involves positive allosteric modulation of the GABAA receptor complex in the central nervous system. Epiphen binds to a specific site on the GABAA receptor, distinct from the binding site of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This interaction enhances the binding and function of GABA, which is the brain's principal inhibitory signal.

Mechanistically, binding of Epiphen prolongs the duration that the chloride ion Cl^- channel remains open. The resulting increased influx of Cl^- ions into the postsynaptic neuron causes hyperpolarization of the neuronal cell membrane. This hyperpolarization elevates the action potential threshold, leading to decreased neuronal excitability and reduced propagation of electrical signals. This modulation influences the activity of the polysynaptic midbrain reticular formation, altering overall central nervous system dynamics.

Dosage and Administration Information

Administration and Usage

Epiphen (phenobarbital) is administered primarily via the oral route as tablets or an oral solution for long-term maintenance therapy. The medicine is also supplied as an injectable solution for Intramuscular (IM) and Intravenous (IV) use, which are generally reserved for acute clinical settings or when oral intake is not feasible.

The standard adult oral maintenance dose for anticonvulsant use typically ranges from 60 mg to 200 mg per day. Due to the compound's long half-life, this daily dose is often administered once daily, although it may be given in two or three divided portions. For the urgent management of acute seizures, the intravenous route requires a slow infusion, with the administration rate not exceeding 60 mg per minute in adults.

Clinical practice involves the use of lower initial doses for older adults compared to younger patients, reflecting diminished drug clearance. For pediatric patients, dosing is determined based on body weight, typically ranging from 3 mg/kg/day to 8 mg/kg/day. The injectable solution must be diluted before intravenous use and administered in a closely supervised environment. Maintenance of the medication typically involves long-term management, and any eventual discontinuation is achieved through gradual dose reduction over an extended period.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Epiphen (Phenobarbital)


Research Evidence for Chronic Seizure Disorders

Epiphen (Phenobarbital) was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations, such as generalized convulsive seizures and certain types of partial seizures. Research examined how seizure frequency changed over defined time intervals in observed populations, using Randomized Controlled Trials (RCTs) and other comparative designs. The primary outcomes reflecting daily functioning or activity level that researchers focused on were the number of seizures a person experienced and the achievement of seizure-free periods.

Early, pivotal research was observed in regulatory reviews, noting Phenobarbital's long-standing inclusion as an Antiepileptic Drug (AED) on essential medicines lists. However, the main body of research on Epiphen's long-term evaluation is considered historical. This means there is limited information for long-term outcomes in recently published, large-scale RCTs that meet current methodological standards. Research exploring modern patient-reported outcomes describing perceived discomfort or quality of life is not fully established or comprehensive compared to the data on seizure rates.


Evidence for Managing Acute, Prolonged Seizures (Status Epilepticus)

Epiphen was evaluated in research scenarios focusing on episodes where symptoms become more noticeable, as part of regimens examined for Status Epilepticus (SE). Studies monitored outcomes describing episodic or acute changes, including the time it took to achieve the cessation of clinical seizure activity and the proportion of patients who stopped seizing within a specific time frame.

Because this is a critical, acute scenario, the research is largely comparative evidence. Subgroup findings are uncertain due to variability in protocols, meaning findings were mixed across different reports. The body of high-quality RCTs is more limited compared to its use for chronic seizure disorders.

Key Studies & References WHO Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Epiphen (FAQ)

Q: Is Epiphen considered a controlled substance in the US?

A: Yes, regulatory authorities in the United States classify Epiphen (Phenobarbital) as a Schedule IV controlled substance. This categorization is based on official determinations regarding its accepted medical use and its established potential for abuse or dependence.


Q: How long does it usually take to feel the effects of Epiphen?

A: According to the official product information, the oral tablet formulation of Epiphen (phenobarbital) is described as typically having an onset of action that occurs within 30 minutes of administration. The medicine is used for long-term neurological stability.


Q: If I miss a dose of Epiphen, what generally happens?

A: General patient guidance suggests that if a dose is missed, it is often recommended to take it as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose is usually skipped. Official guidance typically advises against taking a double or extra dose to compensate.


Q: Is there a risk of dependency or withdrawal associated with Epiphen?

A: Regulatory documents state that phenobarbital may be habit forming and carries an associated risk of psychological and/or physical dependence. Due to this risk, the medicine is directed to be gradually reduced over time, as abrupt cessation after prolonged use may lead to severe withdrawal symptoms, including convulsions.


Q: Does Epiphen affect sleep patterns?

A: Yes, adverse reactions documented in official labels frequently relate to the central nervous system, which includes effects that impact sleep. Common effects include drowsiness, sedation, and lethargy. Less often, effects like insomnia or other sleep disturbances have also been reported.


Q: Is it common for people to experience nausea when they first start taking Epiphen?

A: Official prescribing information documents nausea and vomiting as reported adverse reactions associated with phenobarbital use. These are not always listed among the most common effects but are recognized as possible reactions.


Q: Does Epiphen interact with common over-the-counter pain relievers?

A: Authoritative information indicates that using phenobarbital concurrently with a common pain reliever like acetaminophen may alter the effects of acetaminophen in the body. This combination may also be associated with side effects affecting the liver.


Q: Can elderly patients use Epiphen, and are there special considerations?

A: Official product information notes that older adults may be more susceptible to Central Nervous System effects, such as excitement, depression, or confusion. Due to potential differences in how the drug is cleared from the body, a lower initial dose is often required for these patients.


Q: Are there any long-term effects of taking Epiphen that have been studied?

A: Long-term exposure is known to be associated with the risk of drug dependence. Chronic use has also been associated with risks like decreased bone mineral density and, in rare instances, megaloblastic anemia.


Q: Does taking Epiphen impact the effectiveness of birth control pills?

A: Yes. Official documents indicate that phenobarbital may make oral contraceptive pills and other hormone-based birth control methods less effective. This occurs because the medication can accelerate the metabolism of the hormones in the birth control.


Q: What is the expected duration of action for a single dose of Epiphen?

A: The duration of action for a single dose of the oral tablet formulation of phenobarbital is reported in official clinical documentation to range from 5 to 6 hours. This long duration supports its use for maintenance therapy.


Q: Is it normal to feel a bit restless when starting Epiphen?

A: While sedation is a common effect, phenobarbital can rarely cause restlessness or excitement in some individuals. In children, effects like irritability and hyperactivity can occur instead of drowsiness.


Q: Does Epiphen cause any sensitivity to sunlight?

A: Some authoritative drug information suggests that phenobarbital may be associated with increased sensitivity to the sun (photosensitivity). This effect could amplify the risk of sunburn or skin rash upon sun exposure.


Q: Is Epiphen safe for use in children, based on regulatory approvals?

A: Phenobarbital is approved for use as an anticonvulsant in children according to regulatory documentation, with the dosage calculated based on body weight. However, it has been reported to be associated with some risk of cognitive deficits in pediatric patients.


Q: Can Epiphen be taken by people with kidney issues, according to official information?

A: Regulatory documents place restrictions on the use of phenobarbital in patients with severe renal impairment (severe kidney issues). The use of the medicine may require special consideration or dose adjustment in patients with less severe kidney function impairment.


Q: Are there non-drug interactions, like herbal supplements, mentioned for Epiphen?

A: Official-context information indicates possible interactions with certain herbal products. These include St. John's wort, kava, and valerian, which may increase sedation or affect the way the drug works in the body.


Q: Does Epiphen affect mood or cause emotional changes?

A: Yes, phenobarbital is documented in regulatory labels to cause adverse reactions under Psychiatric Disorders. These include emotional disturbances, abnormality in thinking, anxiety, confusion, and a warning regarding the risk of suicidal ideation and behavior.


Q: Why do official documents emphasize the importance of consistent use of Epiphen?

A: Consistent use is implied as important for maintaining stable blood levels needed for effective seizure control. Official documents emphasize that the medicine must be withdrawn gradually to prevent the risk of severe withdrawal symptoms, which can include convulsions.


Q: Are there any specific lifestyle adjustments recommended while using Epiphen?

A: Regulatory warnings advise against consuming alcohol while using Epiphen. Patients are also cautioned about performing potentially hazardous tasks, such as driving a car or operating machinery, due to the risk of impaired mental and physical abilities.


Q: Does Epiphen affect the ability to drive or operate machinery?

A: Official prescribing information contains cautions that phenobarbital may impair the mental and/or physical abilities required for the performance of hazardous tasks. This warning applies to activities such as driving a car or operating machinery.


Q: Are there specific symptoms that warrant immediate medical attention while on Epiphen?

A: Specific serious symptoms are documented in regulatory labels, and their occurrence is often noted as a reason to seek immediate medical review. Examples include signs of a severe allergic reaction (such as swelling of the face or throat) or signs of a serious skin reaction like blistering or a spreading red/purple rash (e.g., Stevens-Johnson syndrome).


Q: Are there any known interactions between Epiphen and vitamins or mineral supplements?

A: Long-term use of phenobarbital is known to be associated with decreased levels of certain nutrients in the body, specifically folate and vitamin D. Due to this association, adjustment or monitoring of Vitamin D supplementation may be necessary.

How should Epiphen be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define strict guidelines for storing and disposing of medications like Epiphen (Phenobarbital) and EpiPen (Epinephrine Auto-Injector).

Storage Conditions:

The product must be stored at a Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F). It is mandatory to protect the medicine from light, and both excessive heat and freezing are prohibited, meaning refrigeration is not allowed for the auto-injector.

Packaging and Stability:

Keep the product in its original, tightly closed container or carrier tube. The product should be replaced by its expiration date or sooner if the solution appears discolored or contains solid particles, according to stability requirements.

Disposal Rules:

Used auto-injectors are classified as sharps and must be placed immediately into an FDA-cleared sharps disposal container. Unused or expired medications, especially controlled substances like Phenobarbital, must be destroyed in compliance with local regulations and should utilize official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epiphen found in:

A-Z Index: